# BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

> **NCT03943472** · EARLY_PHASE1 · UNKNOWN · sponsor: **Hrain Biotechnology Co., Ltd.** · enrollment: 10 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Anti-BCMA CAR-T cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Immune inhibitors

## Key facts

- **NCT ID:** NCT03943472
- **Lead sponsor:** Hrain Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-08
- **Primary completion:** 2021-11
- **Final completion:** 2022-05
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2021-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03943472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03943472, "BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03943472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*